Document Detail

Darbepoetin alfa in systolic heart failure.
MedLine Citation:
PMID:  23902507     Owner:  NLM     Status:  In-Data-Review    
To the Editor: In their report on the Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) trial, Swedberg et al. (March 28 issue)(1) conclude that the correction of anemia with the use of darbepoetin alfa in patients with heart failure does not reduce the rate of cardiovascular end points. This finding is in line with the results of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).(2) However, it may be difficult to generalize such results to all forms of anemia in heart failure, especially to anemia caused by iron deficiency. As found by Toblli et al. . . .
Dimitrios Farmakis; John Parissis; Gerasimos Filippatos
Related Documents :
22941497 - Vitamin d deficiency is associated with increased left ventricular mass and diastolic d...
20739407 - Acute myocardial infarction caused by coronary embolization of a papillary fibroelastom...
15055817 - Myocardial adaptation in different endurance sports: an echocardiographic study.
19147047 - Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance...
18095257 - Bone marrow-derived myofibroblasts contribute functionally to scar formation after myoc...
12950527 - Use of nonantiarrhythmic drugs for prevention of sudden cardiac death.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The New England journal of medicine     Volume:  369     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2013 Aug 
Date Detail:
Created Date:  2013-08-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  487-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Darbepoetin alfa in systolic heart failure.
Next Document:  Monetary costs of dementia in the United States.